Clinical Trials Browser

OTHER × Cirrhosis, Familial, with Pulmonary Hypertension × 90 days × Clear all

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07224737 2026-03-13

EXOMIC

Completed

230 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Liver Neoplasms, Recurrence, Cholangiocarcinoma

NCT07225452 2026-03-13

LUMIC

Completed

535 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Liver Neoplasms, Cholangiocarcinoma

NCT06859684 2026-03-09

HAIC-quad

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Phase 2 Terminated

1 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

36 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07337850 2026-01-13

FAPi-2

Recruiting

60 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07304388 2025-12-30

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC

Phase 2 Completed

96 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Clinical Trials

A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma

EXOMIC

LUMIC

HAIC-quad

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

FAPi-2

HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC